Biotech company Alchemia has announced a significant breakthrough for the antibiotic stream of its early stage drug discovery platform.Independent test results confirmed Alchemia’s novel class of antibiotic compounds could revolutionise the treatment of the most serious hospital-acquired infections.Alchemia managing director Tracie Ramsdale said the results proved Alchemia’s compounds were highly active against multi-drug resistant organisms.She said these findings could potentially be the most extraordinary scientific development in several decades in the fight against a broad range of multidrug resistant gram-positive bacterial strains.
